Paul Marik Repurposed Drug Protocol for Cancer

Overview

Dr. Paul Marik, a former critical care physician and co-founder of the Front Line COVID-19 Critical Care Alliance (FLCCC), developed a comprehensive cancer protocol centered on repurposed, off-patent medications that target multiple oncogenic pathways simultaneously. The protocol is detailed in his book Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer (2nd edition) and published through IMA Health. The framework treats cancer as a disease of dysregulated metabolism and aberrant cell signaling, reasoning that a multi-drug approach using safe, inexpensive compounds may interrupt these pathways at low cost and with a favorable safety profile.

The foundational layer consists of four agents: ivermectin, mebendazole, doxycycline, and curcumin. These were selected for their well-characterized anticancer mechanisms — including inhibition of cancer stem cells (CSCs), disruption of Wnt/β-catenin and Hedgehog signaling, mitochondrial targeting, and induction of apoptosis — alongside their long established safety records. A second tier of agents is layered on top: atorvastatin, metformin, melatonin, zinc, and vitamin D3. Together, this combination is designed to achieve broad disruption of tumor cell survival pathways while supporting normal cellular function.

Dosing in the protocol is drawn primarily from the systematic clinical review by Halma, Tuszynski, and Marik (2023) published in Nutrients, which classifies the strength of evidence for each agent and provides proposed clinical doses. The protocol is generally used as an adjunct to standard oncology care rather than a replacement. It is important to note that most evidence for these individual agents is preclinical (cell and animal studies) or derived from small case reports and retrospective series; large randomized controlled trials across the full protocol are largely absent or ongoing.

Dosage and Schedule

The following table summarizes the proposed clinical doses drawn from the Halma, Tuszynski, and Marik 2023 review in Nutrients. Doses are intended to be individualized by a treating physician based on patient weight, renal/hepatic function, concurrent medications, and tumor type. Higher or lower doses within published ranges may be appropriate in specific contexts.

Mechanism of Action

A central premise of the Marik protocol is that combining agents with complementary and overlapping mechanisms may achieve more comprehensive tumor suppression than any single agent alone. Each compound targets one or more distinct oncogenic pathways.

Ivermectin

Ivermectin, an FDA-approved antiparasitic, has demonstrated multifaceted anticancer activity across numerous cancer types. Its primary anticancer mechanism involves degradation of PAK1 kinase — a serine/threonine kinase that drives proliferation, invasion, and angiogenesis across most solid tumors — via ubiquitin-mediated proteolysis, disrupting downstream Wnt/β-catenin, Akt/mTOR, and MAPK signaling. Ivermectin also directly binds HSP27, blocking stress-adaptive survival signaling and sensitizing cancer cells to anti-EGFR and anti-androgen receptor therapies.

Beyond these primary targets, ivermectin promotes both intrinsic and extrinsic apoptosis across multiple cancer types, inhibits AKT/mTOR to induce cytostatic autophagy, and reverses multidrug resistance by inhibiting EGFR/ERK/Akt/NF-κB signaling at sub-cytotoxic concentrations. Preclinical evidence demonstrates that ivermectin selectively depletes immunosuppressive myeloid cells and regulatory T cells, enhances effector T-cell activity, and synergizes with anti-PD-1 checkpoint inhibitors in breast cancer models.

Mebendazole

Mebendazole (MBZ), a benzimidazole anthelmintic, achieves anticancer effects primarily through β-tubulin binding. By depolymerizing microtubules at low concentrations (EC₅₀ ~132 nM), mebendazole induces mitotic arrest, upregulates p53/p21, and triggers apoptosis. It also inhibits the Sonic Hedgehog/GLI1 signaling pathway — a major driver of cancer stem cell self-renewal — at IC₅₀ 0.516 μM, positioning it as a potential alternative to vismodegib. Mebendazole reduces VEGFR2 kinase activity and tumor microvessel density, inhibits BRAF/MEK signaling including BRAFⅤ⁶⁰⁰ᴴ, and depletes ALDH+ cancer stem cells in triple-negative breast cancer.

A particularly relevant property is mebendazole’s ability to cross the blood-brain barrier, making it especially applicable in primary and metastatic brain tumors. Preclinical data also show that mebendazole polarizes tumor-associated macrophages toward a pro-inflammatory M1 anti-tumor phenotype, enhancing immune cell killing of tumor cells.

Doxycycline

Doxycycline, a tetracycline-class antibiotic, targets cancer stem cells through mitochondrial mechanisms. By inhibiting the small mitochondrial ribosome, doxycycline suppresses translation of mitochondrial-encoded proteins (MT-ND3, MT-CO2, MT-ATP6, MT-ATP8) by up to 35-fold, reducing oxidative phosphorylation capacity. Because cancer stem cells preferentially rely on mitochondrial OXPHOS, doxycycline selectively depletes CD44+/ALDH1+ CSC populations while largely sparing differentiated tumor cells and normal tissue. Preclinical work by Lisanti et al. demonstrated that doxycycline and related mitochondria-targeting antibiotics could eradicate CSCs from 12 cancer types across 8 tumor models at sub-antimicrobial concentrations.

Doxycycline also reduces epithelial-to-mesenchymal transition markers in breast cancer, induces ATF4-mediated ER stress and PUMA-dependent apoptosis specifically in CSC-like cells, and sensitizes cancer cells to gemcitabine-induced apoptosis. A clinical pilot study in early breast cancer demonstrated approximately 90% reduction in CSC markers (CD44, ALDH1) after just 14 days of pre-operative doxycycline at 200 mg/day.

Curcumin

Curcumin, the active polyphenol in turmeric (Curcuma longa), acts through pleiotropic mechanisms. It suppresses NF-κB — the master transcriptional regulator of inflammation and tumor survival — reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and COX-2 expression. Curcumin induces G2/M and G1 cell cycle arrest, activates intrinsic and extrinsic apoptotic pathways, and inhibits multiple kinase cascades including PI3K/Akt/mTOR, EGFR, JAK/STAT3, and MEK/ERK. It also downregulates VEGF, VEGFR, MMP-2, and MMP-9, reducing tumor neo-vascularization.

A systematic review of clinical trials published in BMC Cancer (2020) found that curcumin supplementation increases the effectiveness of chemotherapy and radiotherapy in cancer patients. A critical limitation is that native curcumin has very poor oral bioavailability (approximately 1%). Bioavailability-enhanced formulations — phospholipid complexes, nanoparticles, or piperine co-administration — are considered essential for achieving therapeutic plasma levels.

Atorvastatin

Atorvastatin inhibits HMG-CoA reductase, depleting mevalonate pathway intermediates (farnesyl pyrophosphate, geranylgeranyl pyrophosphate) required for post-translational prenylation of Ras/Rho GTPases that drive tumor proliferation and invasion. This mechanism also triggers intrinsic apoptosis in multiple tumor types, reduces anti-apoptotic Bcl-2 family members, suppresses VEGF expression, and modulates tumor-associated macrophage-mediated immunosuppression. Observational epidemiologic data suggest reduced cancer incidence and mortality in statin users across several tumor types, and head and neck cancer trials have explored atorvastatin as an adjuvant radioprotective agent.

Metformin

Metformin activates AMP-activated protein kinase (AMPK) via LKB1, which then inhibits mTORC1, reducing protein synthesis, cell growth, and anabolic tumor metabolism. It also directly inhibits mitochondrial Complex I, lowering ATP production and raising the AMP:ATP ratio. By lowering circulating insulin and IGF-1, metformin reduces PI3K/Akt/mTOR pro-survival signaling. Epidemiologic studies consistently show that diabetic patients on metformin have lower cancer incidence and mortality compared to those on other glucose-lowering agents, and positive RCT signals have been reported in HER2+ breast cancer and early colorectal cancer.

Melatonin, Zinc, and Vitamin D3

Melatonin at pharmacological doses (20–30 mg) induces apoptosis via mitochondrial ROS generation and cytochrome c release, suppresses the Warburg effect by modulating HIF-1α, inhibits VEGF and MMP-9, and stimulates NK cell and T-cell activity. A meta-analysis of 21 randomized controlled trials reported that adjuvant melatonin at 20 mg/day reduced 1-year mortality (RR = 0.63), improved tumor response rates, and reduced chemotherapy-related toxicities including leucopenia and thrombocytopenia.

Zinc is required for the structural integrity of the p53 tumor suppressor protein (a zinc finger protein); deficiency leads to p53 misfolding and loss of function, and supplementation may restore p53 activity. It also supports T-cell and NK-cell activity — zinc deficiency is common in cancer patients and correlates with poorer outcomes. Vitamin D3 acts through the vitamin D receptor (VDR), which regulates more than 200 genes involved in cell cycle control, apoptosis, differentiation, and immune function. Vitamin D deficiency (serum level below 20 ng/mL) correlates with worse outcomes across breast, colorectal, prostate, and ovarian cancers, and supplementation studies have shown mortality reduction signals.

Clinical Evidence

The Guerini et al. 2019 review in Cancers collated case reports and series showing mebendazole activity across adrenocortical carcinoma, colon cancer, and other solid tumors. Preclinical work by Borodovsky et al. established mebendazole as a Hedgehog pathway inhibitor with activity competitive with vismodegib, while Gilkes et al. demonstrated eradication of triple-negative breast cancer stem cells. For ivermectin, Huang et al. established PAK1-mediated cytostatic autophagy in breast cancer, and Rana et al. demonstrated synergy with anti-PD-1 checkpoint inhibitors, converting immunologically “cold” breast tumors to “hot” in mouse models.

Metformin carries the strongest clinical evidence base among the Tier 2 agents. Multiple Phase 2 and 3 trials in oncology are ongoing, and epidemiologic consistency across diverse populations supports a real-world anticancer effect. For the broader repurposed drug combination as a unified protocol, data remain limited to the retrospective analyses, case reports, and preclinical work surveyed in the Halma, Tuszynski, and Marik 2023 Nutrients review.

Important Considerations

Several drug-drug interactions require attention when combining these agents. Curcumin inhibits CYP3A4 and CYP2D6 at high doses and may alter levels of chemotherapy drugs including paclitaxel, docetaxel, and tamoxifen. Metformin carries a risk of lactic acidosis in renal impairment and should be held before contrast imaging procedures. Ivermectin at high doses carries CNS effects; concurrent P-glycoprotein inhibitors increase CNS exposure and should be avoided. Atorvastatin combined with certain antibiotics (e.g., azithromycin) creates CYP3A4 interactions that may increase myopathy risk.

Recommended monitoring includes: liver function tests (baseline and every 3 months for mebendazole, atorvastatin, and curcumin); complete blood count periodically (mebendazole can rarely cause neutropenia); renal function at baseline and during metformin use; serum 25-OH Vitamin D titrated to 55–90 ng/mL with calcium and parathyroid hormone monitoring; zinc and copper levels with long-term high-dose zinc use; and blood glucose and HbA1c for metformin use.

This protocol comprises exclusively off-label uses of approved medications. It is not FDA-approved for cancer treatment. The evidence base, while biologically compelling, consists primarily of preclinical data, case reports, and retrospective analyses. Patients should be managed by a physician experienced in drug interactions, monitoring requirements, and integration with standard oncology care.